Chapter 4: Patient-Focused Drug Therapy & Cultural Care

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive, the place where we cut through the information noise to get you seriously well informed.

Today, we're diving into pharmacology, but we're shifting our focus entirely.

We aren't just discussing how a specific drug works.

We're exploring how you, the patient, fundamentally alter that drug's performance.

That's really the core mission today.

We're looking at these patient -focused considerations, things like your age, pregnancy status, maybe your ethnocultural background, and revealing how they just change everything about safe dosing and, you know, effectiveness.

And the reason this matters so much, as our source material clearly out, is this huge knowledge gap.

I mean, most clinical trials historically anyway focus on adults, right?

Maybe 13 to 65.

Right, that's standard range.

Which leaves these vast stretches of the patient population, what the source calls the two ends the spectrum of life, so kids and older adults, relying on, well, guesswork almost,

extrapolated data.

It's often extrapolated data, exactly.

And the consequence is that these patient factors, they dramatically impact the four phases of pharmacokinetics, absorption, distribution, metabolism, and excretion, you know, ADME.

ADME, yeah.

And if those phases change,

the risk of serious side effects or toxicity changes predictably, but often dangerously too.

Yeah.

We really have to know where those differences are.

Okay, let's unpack this.

We should probably start our journey with perhaps the most sensitive population, pharmacotherapy, during pregnancy and lactation.

Right, so when a drug moves from the mother to the fetus, the main way it happens is simple passive diffusion, just moving across the placental barrier.

Okay, so passive diffusion means no energy needed.

It's just moving, like you said, from high concentration in the mom's blood to lower concentration in the baby's blood.

That's different from active transport, which needs energy, needs pumps on the cells.

Exactly.

And there are three big categories of factors that determine the overall risk to the fetus.

First, it's the drug properties themselves.

We're talking chemistry here.

Molecular weight.

Is the drug lipid soluble, you know, fatty or water soluble?

How much does it bind to protein in the blood?

And of course, the dose and how long the therapy lasts.

If it's small and fat soluble, it crosses that placenta much more easily.

Makes sense.

And the second factor is fetal gestational age, which you mentioned creates this kind of paradox.

Risk versus transfer rate.

It really does.

And listeners should probably note this distinction.

The highest risk for developmental anomalies, birth defects,

is actually in the first trimester.

Okay.

Because that's when you have incredibly rapid cell growth and organogenesis, the organs are forming.

But the highest drug transfer rate, that doesn't happen until the last trimester.

Why is that?

Because that's when the blood flow to the placenta is maxed out and the surface area for exchange is at its peak.

More drug gets across later.

So the potential for actual damage is early, but the greatest amount of drug exposure is late.

Huh.

And the third factor is all about the mother's health, right?

Maternal factors.

Absolutely critical.

If the mother has liver or kidney issues, she can't clear the drug effectively herself.

Right.

That means higher drug levels in her system and prolonged exposure for the fetus.

Also, and this is key, a mother's individual genetics, her genotype, can affect how quickly she metabolizes certain drugs.

That directly influences the dose circulating.

This complexity really highlights why those old ABCDX drug safety categories were just too simple and why they've been replaced since 2015 with a much more detailed labeling system.

Yeah.

That new system gives much more useful detailed narrative subsections.

Instead of just a letter grade, you get specifics under three main headings.

Pregnancy talks about risk, dosing, maybe registry info, then lactation, how much drug gets into breast milk, potential effects on the baby.

And females and males have reproductive potential info on fertility, contraception, pregnancy testing.

It lets clinicians make a much more informed case by case decision.

Right.

Much more nuanced.

And speaking of lactation, the focus is often on avoiding transfer through breast milk, but is that actually the main way most drugs leave the body?

No, generally it's not the primary excretion route,

but drugs definitely still transfer, especially those that are fat soluble, non -ionized, and have a low molecular weight.

They slip into the milk more easily.

Okay.

Ultimately though, the decision to breastfeed while taking medication always comes down to a careful risk benefit calculation.

You have to weigh the very clear benefits of breastfeeding against any potential harm from the drug exposure.

It's always individualized.

Okay.

That makes sense.

Now let's pivot, like you said, to the other end of the lifespan pediatric patients.

So we're talking neonates under a month old, all the way up to adolescence, 13 to 19 years.

And the central challenge here is immaturity, right?

Organs aren't fully cooked yet.

That immaturity creates some

really striking differences in pharmacokinetics.

Let's just look at absorption.

Until a child is maybe one or two years old, their stomach pH is less acidic.

The acid producing cells just aren't fully mature.

Okay.

So that affects how drugs dissolve.

Exactly.

Drugs that need an acidic environment won't be absorbed as well.

Also gastric emptying is slower,

peristalsis is sluggish, and their immature liver means reduced first pass elimination.

Ah, right.

Less first pass effect means more drug gets into the system initially.

Exactly.

It's essentially like giving a higher effective dose without meaning to.

Now moving to distribution, this is where the differences can be really dramatic.

Infants, especially preemies, have a much higher percentage of total body water.

Could be up to 85%.

Wow.

So that sounds like a dilution issue for water soluble drugs?

It absolutely is.

Water soluble drugs get spread out over a larger volume.

At the same time, their protein binding is decreased.

Why?

The immature liver produces less protein, like albumin.

Okay.

So if you give a drug that normally binds heavily to protein, think phenytoin for seizures, there's much less protein for it to bind to.

That means a much higher level of unbound active drug is floating around freely in the blood.

Which significantly increases the risk of toxicity.

Hugely.

And on top of that, we have to remember the immature blood brain barrier.

It's like a less secure gate.

It allows more drug to get into the central nervous system, which could definitely enhance side effects or toxicity right in the brain.

Okay.

That's a lot to consider just for distribution.

And it continues with metabolism and excretion.

The whole engine is running slower initially.

Liver microsomal enzymes, the P450 system, are decreased at first.

And kidney function is immature.

That means a lower glomerular filtration rate, or GFR,

and less efficient tubular function.

So drugs hang around longer.

They're metabolized slower and excreted slower.

That leads to accumulation and means you often need really significant dose reductions compared to adults.

And it's not just about how the body handles the drug, the kinetics.

The sensitivity of rapidly developing tissues means the differences are also in pharmacodynamics, how the drug actually affects the body.

We see this with some really serious contraindications.

Yeah, specific examples are important here.

Like tetracycline antibiotics causing permanent tooth discoloration in kids.

Or systemic corticosteroids suppressing growth.

And even quinolone antibiotics possibly damaging cartilage.

These aren't just side effects.

They can be

directly tied to the patient's age.

Here's where it gets really interesting.

How does a clinician actually navigate this minefield of variability?

How do you calculate a safe dose for a child?

Well, we rely mainly on two methods.

The most common is probably the body weight method.

Straightforward MGKG dosing.

Okay.

You calculate the dose based on the child's weight in kilograms.

And then this is crucial.

You compare it to the known safe daily dosage range for that drug,

the minimum and maximum milligrams per kilogram per day.

But you mention a gold standard, especially for riskier meds or tiny babies,

the body surface area BSA method.

Right.

The BSA method is generally considered more accurate.

It accounts for the relationship between height and weight, which gives a better estimate of metabolic mass and therefore metabolic and excretion capacity.

How does that work in practice?

Clinicians often use graphical tools, nomograms, like the West Nomogram.

You plot the child's height in centimeters and weight in kilograms on this chart.

And where the line connecting them crosses a central scale, that gives you the estimated body surface area in meters squared.

It provides a calculation that's less prone to error than weight alone, especially at the extremes of size.

Okay.

Which brings us squarely to safety.

When you're managing these doses,

what's the single most critical safety rule?

The one that if you ignore it can lead to absolutely tragic errors.

You must use the patient's weight in kilograms, always.

Confusing pounds in kilograms is repeatedly cited as the single biggest source of major dosing errors in pediatrics.

Wow.

Clinicians absolutely have to calculate that safe range using kilograms in comparison to the prescribed dose every single time.

It's just, it's non -negotiable, a fundamental safety check.

That is definitely a life or death conversion to get right.

Okay.

Let's jump now to the other end of that spectrum.

The older adult defined as 65 and up.

This population is growing fast and they face, well, a double -barreled threat, really.

Polymorbidity.

Multiple chronic illnesses, yeah.

And polypharmacy.

Polypharmacy.

Taking lots of different drugs concurrently.

Often prescription, but also over -the -counter stuff.

Herbals.

You know, it's not uncommon to see patients on 10 or more medications.

And that is perhaps the single greatest pharmacological danger in this group.

And the numbers quantifying that risk are just staggering.

They really are.

The source notes that the risk of a drug -to -drug interaction is about 50 % if a patient is taking just five medications.

50%.

Yeah.

Now get them up to 10 or more medications, that risk skyrockets to essentially guarantee 100 % chance of an interaction.

Wow.

And this often happens because of something called the prescribing cascade.

A doctor prescribes drug A, it causes a side effect, so they prescribe drug B to treat the side effect of drug A, and maybe drug B causes another side effect that becomes a chain reaction.

A cascade, yeah.

Okay, so let's detail the physiological decline that makes them so vulnerable.

How does ADME change in the aging body?

Table 4 .3 in the source lays this out clearly.

Right.

Let's start with absorption.

It's generally reduced.

Older adults often produce less stomach acid, so the gastric pH increases, becomes less acidic.

That affects drug dissolution.

Plus, blood flow to the GI tract can be reduced by 40, even 50%.

And decreased muscle tone and motility, often leading to constipation and laxative use,

further slows things down.

And then distribution changes because body composition shifts, right?

Exactly.

Body composition changes quite dramatically over time.

Total body water gradually reduces, so water soluble hydrophilic drugs become more concentrated in a smaller volume.

Okay.

Conversely, body fat tends to

lean mass.

This adds like a reservoir, a long -term storage site for fat soluble lipophilic drugs.

Think about many sedatives or hypnotics.

Their effects can be prolonged because they're slowly leaching out of fat stores.

And just like we saw in infants, but for different reasons, there are issues with protein binding.

Yes, this time is due to organ decline.

The aging liver often produces fewer proteins, particularly albumin.

This reduced protein binding means more free, active drug is circulating, unbound.

So higher risk again.

Especially for drugs that are normally highly protein bound, like warfarin, the anticoagulant, or phenytoin.

Even a small change in dose or protein levels can cause a massive jump in the active drug concentration, pushing the patient into toxicity really fast.

Okay.

And for metabolism and excretion, are the systems just wearing down?

That's a good way to put it.

Metabolism definitely slows.

Liver mass decreases, the production of those crucial P450 enzymes reduces, and blood flow to the liver declines steadily, maybe by 1 .5 % per year after age 25.

All this prolongs the half -life of many medications.

They stick around longer.

And excretion through the kidneys.

That also declines significantly.

Maybe 40 to 50 % of older adults see a measurable drop in their glomerular filtration rate, the GFR.

Their kidneys just aren't clearing drugs as efficiently.

Fewer intact nephrons, too.

This delay means they're at high risk of drug accumulation, especially dangerous with drugs that have a narrow therapeutic index, like digoxin for heart failure.

It sounds like the cumulative effect of all these changes is just heightened, almost unpredictable sensitivity, which makes that cardinal dosing rule absolutely crucial.

Start low and go slow.

That's the mantra.

And thankfully, we have some tools to help manage this complexity.

The Beers Criteria, which was last updated in 2019, is really indisputable.

How does that help?

It's a list that helps clinicians systematically identify potentially inappropriate medications PIMs for older adults.

Using it helps significantly reduce adverse drug events.

And given that declining GFR we mentioned, regular monitoring of kidney function like checking the estimated GFR and liver function test, that's an absolute baseline safety requirement.

Okay, so we've covered the cultural and, importantly, a genetic entity.

We're moving into this area called drug polymorphism.

Right.

Drug polymorphism is basically the recognition that all these different variables, age, gender, size, body composition, diet, cultural factors, and especially genetics,

all influence how an individual patient responds to a drug.

The genetic variation in metabolism alone is just staggering.

Let's try to nail down some specific genetic examples from the source, because they have really immediate dosing consequences.

It often boils down to how fast your body acetylates or metabolizes a drug using certain enzymes, right?

That's a major factor.

For instance, looking at acetylators, some people, particularly those of European and African descent, are genetically classified as slow acetylators.

They metabolize certain drugs like isoniazid for tuberculosis very slowly.

They need lower doses to avoid toxic buildup.

But on the flip side, some people, maybe of Japanese or Inuit descent, can be rapid acetylators.

They might chew through the drug so quickly they need significantly higher doses just to get a therapeutic effect.

And the variation in our main detoxifying system in the liver, the cytochrome P450 enzymes, that's even more common, isn't it?

Oh, absolutely.

It's a huge reason why trial and error dosing is so common and often frustrating, especially with certain drug classes.

Take psychotropic drugs, for example.

Okay.

The source points out that many patients of Asian descent are genetically predisposed to being poor metabolizers of these specific drugs through certain P450 pathways.

Standard doses might be toxic for them.

Contrast that with some white patients who might be ultra rapid metabolizers through the same pathway and need much higher doses to see any benefit at all.

It shows drug response is fundamentally tied to ancestry and individual genetic makeup.

And beyond pure genetics, culture itself profoundly dictates health beliefs, practices, and even adherence.

For indigenous peoples in Canada, health is often seen through a very holistic lens focusing on interconnectedness.

Yes, a really important concept.

They often conceptualize health using the medicine wheel, which emphasizes balancing four key aspects, physical, emotional, intellectual, and spiritual health.

Illness is seen as a sign of imbalance in one or more of these areas.

And that influences treatment approaches.

Definitely.

Traditional healing practices, which might include smudging using sacred medicines like tobacco, sage, sweet grass, and cedar, or consulting traditional healers.

These must be acknowledged, understood,

and respectfully integrated, or at least considered alongside conventional

pharmaceuticals.

You need to ask.

And we see similar underlying themes of balance in other cultures, too, like the focus on yin and yang in many Asian cultures.

Absolutely.

And it just underscores the necessity for clinicians to conduct a thorough ethnocultural assessment.

You have to ask about language preferences, health beliefs,

past use of herbal or traditional remedies, any specific religious practices like Christian scientists who typically avoid all conventional medication, and even socioeconomic status.

How does socioeconomic status play in?

Well, the source mentions the barrier of the culture of poverty, where patients might be forced to skip doses or split pills simply because they can't afford the medication.

That's a really serious non -biological reason for non -adherence that needs to be uncovered.

Absolutely critical to understand the whole picture.

Okay.

Finally, let's try to synthesize some crucial implementation safety steps across the lifespan, focusing on what the source really stresses for nurses on the front lines.

Okay.

For pediatric safety, a couple of practical things really stand out.

First, never ever mix medication into essential foods the child needs, like milk or their favorite cereal.

Why not?

You risk the child developing a permanent aversion to that food if they associate it with unpleasant medicine.

Use something neutral or treat -like, maybe sherbet or ice cream, something they don't need to eat regularly.

Also, don't put meds in a full bottle of formula or juice because they might not finish it.

And never call medicine candy.

Good points.

What else for kids?

Be incredibly vigilant about transdermal patches.

If one accidentally falls off and an infant or small child finds it, touches it, puts it on themselves, the high concentration in that patch can lead to really serious, even fatal exposure.

Secure them well and dispose of them properly.

Okay.

And for older adults, the big focus is fighting that polypharmacy danger through medication reconciliation.

That's where the brown bag technique is so valuable.

You ask the patient to literally bring in every single pill bottle, every supplement container, every cream, everything they take in a bag to their appointment or hospital admission.

So you can see everything together.

It's the absolute best way to accurately reconcile their actual medication regimen, identify duplications, interactions, potential polypharmacy issues, and then make sure any new instructions are super simple, maybe in large print, and fully understood by both the patient and any caregivers involved.

Excellent practical advice.

So what does this all mean?

Well, I think it means we absolutely have to treat every single patient as an individual pharmacological case study.

The pharmacokinetic variability across the lifespan is just massive, from that neonates immature organ systems demanding careful BSA dosing, to the older adults physiological decline requiring us to start low and go slow.

And critically, biological aging is really only half the story, isn't it?

Genetic factors fundamentally dictate how quickly we metabolize drugs, sometimes requiring vastly different doses based on ancestry.

And cultural factors, they dictate health beliefs, the use of traditional remedies, and even whether a patient adheres to the prescribed regimen at all.

So individualized care based on age, genetics, and a deep culturally informed assessment, that's the ultimate safety protocol in modern pharmacology.

It really is.

Which leads to a final thought for you, our listener.

Given the dramatic impact of genetic polymorphism on drug metabolism, especially for complex and highly variable drug classes like psychotropics, how rapidly do you think clinical practice will evolve to integrate routine, personalized genetic testing?

Could we potentially eliminate much of the dangerous trial and error dosing that's still so common today?

Something to think about.

A warm thank you from the last minute lecture team.

Thank you for making this deep dive with us.

We hope this was a valuable shortcut to being well informed.